In its report, ICER notes that Wegovy, Mounjaro, and Novo Nordisk's oral semaglutide not yet on the market for obesity are all cost-effective, based on their current prices and the assumption that oral semaglutide will cost the same as the injectable version
May reduce oxidative damage in children with autism Many studies, including a clinical trial reported in Medical Science Monitor Trusted Source, show that children with autism have higher oxidative damage and lower glutathione levels in their brains
(The Washington Post notes that some Part D plans do cover Wegovy if prescribed for reducing cardiovascular risk, or Zepbound for obstructive sleep apnea, but not for obesity ( [38] ) ( [39] ).) In summary, nearly all current GLP-1 weight-loss usage depends on commercial/employer coverage , which is highly variable and restrictive
We combine physician-supervised GLP-1 therapy with personalized nutrition and a realistic exercise plan designed around your schedule because lasting results come from care that fits your life, not the other way around